Maximus Triggers Bearish MACD Death Cross, Bearish Marubozu on 15min Chart
ByAinvest
Thursday, Sep 25, 2025 2:05 pm ET1min read
MMS--
Technical Analysis
The MACD Death Cross, a bearish signal, indicates that the 12-day and 26-day exponential moving averages of the stock's price have crossed over in a downward direction. This often signals a potential reversal in the stock's price trend. Additionally, the Bearish Marubozu signal suggests a strong bearish candle, where the body of the candle is large and the wicks are small, indicating strong selling pressure [1].
Financial Performance
Maximus has shown consistent growth and profitability over the past five years, with a 5Y average top-line growth of 12.65% and a 5Y average EBIT growth of 12.76%. However, there has been a shift in the last twelve months, with top-line growth slowing to 3.4% YoY. Despite this, margins have been expanding, with gross margins and EBIT margins improving significantly compared to the 5Y average [2].
Segmental Analysis
The US Services segment has been the biggest loser this year, with revenue declining by 7-9% YoY each quarter due to tough comparable volumes from last year. The US Federal segment, however, has shown growth, with revenue up 11.4% YoY, driven by higher volumes for their clinical portfolio. The International segment saw a decline of 14.5% YoY due to divestitures, but organic revenue growth offset this decline [2].
Valuation
Maximus is currently trading at a forward P/E ratio of 12x, which is relatively attractive given its expanding margins, buybacks, and growth prospects. The stock's valuation suggests a fair value range of around $146.5 per share, indicating potential upside for investors [2].
Conclusion
While Maximus has shown strong historical performance and a resilient business model, the recent technical signals indicate a potential decline in the stock price. Investors should closely monitor the stock's performance and consider the implications of the bearish signals before making investment decisions.
References
[1] https://www.tradingview.com/news/zacks:da3d73ce2094b:0-zacks-com-featured-highlights-include-universal-health-services-methanex-arista-networks-voya-financial-and-maximus/
[2] https://seekingalpha.com/article/4825087-maximus-a-stable-compounder-trading-at-just-12x-earnings
According to the 15-minute chart of Maximus, a MACD Death Cross and a Bearish Marubozu signal was triggered at 09/25/2025 14:00. This indicates that the stock price has the potential to continue declining, as sellers are currently in control of the market and bearish momentum is likely to persist.
Maximus Inc. (MMS) has experienced significant changes in its stock price dynamics, with a MACD Death Cross and a Bearish Marubozu signal being triggered on September 25, 2025, at 14:00. These technical indicators suggest that the stock price may continue to decline, as sellers are currently dominant in the market and bearish momentum is likely to persist [1].Technical Analysis
The MACD Death Cross, a bearish signal, indicates that the 12-day and 26-day exponential moving averages of the stock's price have crossed over in a downward direction. This often signals a potential reversal in the stock's price trend. Additionally, the Bearish Marubozu signal suggests a strong bearish candle, where the body of the candle is large and the wicks are small, indicating strong selling pressure [1].
Financial Performance
Maximus has shown consistent growth and profitability over the past five years, with a 5Y average top-line growth of 12.65% and a 5Y average EBIT growth of 12.76%. However, there has been a shift in the last twelve months, with top-line growth slowing to 3.4% YoY. Despite this, margins have been expanding, with gross margins and EBIT margins improving significantly compared to the 5Y average [2].
Segmental Analysis
The US Services segment has been the biggest loser this year, with revenue declining by 7-9% YoY each quarter due to tough comparable volumes from last year. The US Federal segment, however, has shown growth, with revenue up 11.4% YoY, driven by higher volumes for their clinical portfolio. The International segment saw a decline of 14.5% YoY due to divestitures, but organic revenue growth offset this decline [2].
Valuation
Maximus is currently trading at a forward P/E ratio of 12x, which is relatively attractive given its expanding margins, buybacks, and growth prospects. The stock's valuation suggests a fair value range of around $146.5 per share, indicating potential upside for investors [2].
Conclusion
While Maximus has shown strong historical performance and a resilient business model, the recent technical signals indicate a potential decline in the stock price. Investors should closely monitor the stock's performance and consider the implications of the bearish signals before making investment decisions.
References
[1] https://www.tradingview.com/news/zacks:da3d73ce2094b:0-zacks-com-featured-highlights-include-universal-health-services-methanex-arista-networks-voya-financial-and-maximus/
[2] https://seekingalpha.com/article/4825087-maximus-a-stable-compounder-trading-at-just-12x-earnings
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet